CTOs on the Move

CreoDent Prosthetics

www.creodental.com

 
CreoDent Prosthetics is a nationally recognized premier full service dental laboratory and a milling center located in New York. With 2 facilities in NYC and Newburgh, NY, CreoDent specialize in both implant and esthetic dentistry. CreoDent continues to grow and develop new products and services to our clients nationwide. Our products and services have given CreoDent its reputation as the finest dental laboratory to work with.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Sartorius Mechatronics Corporation

Sartorius AG is a Germany-based company engaged in the biotechnology and mechatronics sectors. It provides laboratory and process technology to companies operating in the pharmaceutical, biotechnology, chemical, food and beverage industries.

Utah Medical Products

Utah Medical Products, Inc. is a Midvale, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Prematics

Prematics, Inc is a Mclean, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Child Abuse Listening and Mediation

CALM`s mission is to prevent childhood trauma, heal children and families, and build resilient communities in Santa Barbara County.

BioSig Technologies

BioSig Technologies, Inc. (OTCQB: BSGM) is a medical device company that is developing a proprietary technology platform to address an unmet technology need in the rapidly growing $4.6+ billion electrophysiology (EP) marketplace. Led by a proven management team, world-class Board of Directors and Scientific Advisory Board, Minneapolis-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The PURE EP System is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making crucial clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings even at undetectable levels (until now) with high accuracy to help identify appropriate catheter ablation targets - areas of tissue to destroy that create a heart rhythm disturbance (arrhythmia). BioSig`s main goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. PURE EP is an innovative platform, offering potential benefits over current technologies including increased accuracy, reduced noise and interference, clinical information previously not available and potential elimination of the need for repeat procedures. BioSig has partnered with Minnetronix on technology development and is working toward FDA 510(k) clearance for the PURE EP System.